Although drug-eluting stents are still the default interventional treatment of coronary artery
disease, drug-coated balloons (DCBs) represent a novel alternative therapeutic strategy in …

Percutaneous coronary intervention with a drug-eluting stent is the most common mode of
revascularization for coronary artery disease. However, restenosis rates remain high. Non …

Background In the treatment of de-novo coronary small vessel disease, drug-coated
balloons (DCBs) are non-inferior to drug-eluting stents (DESs) regarding clinical outcome up …

Objectives This study sought to compare the performance of a novel drug-coated balloon
(DCB)(Elutax SV, Aachen Resonance, Germany), with an everolimus-eluting stent …

Abstract Background Drug-coated balloons (DCBs) are accepted treatment strategies for
coronary in-stent restenosis and are under clinical investigation for lesions without prior …

Drug-coated balloon (DCB) technology was developed to deliver the antiproliferative drugs
to the vessel wall without leaving any permanent prosthesis or durable polymers. The …

Background Native vessel coronary artery disease represents 1 of the most attractive fields
of application for drug-coated balloons (DCBs). To date, several devices have been …

Objectives The study sought to evaluate the impact of diabetes mellitus on 3-year clinical
outcome in patients undergoing drug-coated balloon (DCB) or drug-eluting stent (DES) …

Despite significant goals achieved in diagnosis and treatment in recent decades, coronary
artery disease (CAD) remains a high mortality entity and continues to pose substantial …

Drug-coated balloon treatment in coronary artery disease: Recommendations from an Asia-Pacific
Consensus Group Page 1 Address for correspondence: Eun-Seok Shin, MD, PhD, Division of …